Certain genotypes of human papillomavirus (HPV), the most common viral infection of the reproductive tract, have been shown to cause of range of conditions in both men and women including precancerous and cancerous lesions.  In fact, HPV types 16 and 18 are believed to be responsible for 70% of all cervical cancers worldwide.  New vaccines designed to protect against HPV 16 and 18 infection have the potential to reduce the incidence of cervical and other anogenital cancers.

Featured Articles

Yes Comprehensive control of human papilloma virus infections and related diseases
F. Xavier Bosch, Thomas R. Broker, David Forman, et al

Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal...

No Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States—Do we need a broader vaccine policy?
N. Osazuwa-Peters

Human papillomavirus (HPV) is a sexually transmitted infection (STI) of global importance; it is the most prevalent STI in the United States, with...

No Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons
Kelly L. Donahue, Nathan W. Stupiansky, Andreia B. Alexander, Gregory D. Zimet

Routine administration of the quadrivalent human papillomavirus (HPV) vaccine has been recommended for 11–12-year-old males since 2011, but...

No Systematic review of human papillomavirus vaccine coadministration
Alinea S. Noronha, Lauri E. Markowitz, Eileen F. Dunne

Human papillomavirus (HPV) vaccination is recommended in early adolescence, at an age when other vaccines are also recommended.

No Challenges in cervical cancer prevention: A survey of U.S. obstetrician-gynecologists
Rebecca B. Perkins, Britta L. Anderson, Sherri Sheinfeld Gorin, Jay A. Schulkin

Current cervical cancer prevention recommendations include human papillomavirus (HPV) vaccination, Pap and HPV co-testing, and Pap testing at 3-...

No Human papillomavirus vaccine initiation and awareness: U.S. young men in the 2010 National Health Interview Survey
Peng-jun Lu, Walter W. Williams, Jun Li, et al

In 2009, the quadrivalent human papillomavirus (HPV) vaccine was licensed by the U.S. Food and Drug Administration for use in men/boys aged 9–26...

No Geographic variability in human papillomavirus vaccination among U.S. young women
Feifei Wei, Page C. Moore, Angela L. Green

Little information is available on geographic disparity of human papillomavirus (HPV) vaccination among women aged 18–26 years in the U.S.

No Human papillomavirus vaccine and sexual behavior among adolescent and young women
Nicole C. Liddon, Jami S. Leichliter, Lauri E. Markowitz

Vaccines to prevent certain types of human papillomavirus (HPV) and associated cancers are recommended for routine use among young women.

No Human papillomavirus vaccine among adult women: Disparities in awareness and acceptance
Yan Cui, Susie B. Baldwin, Dorothy J. Wiley, Jonathan E. Fielding

Human papillomavirus (HPV) vaccines have been shown to be safe and highly effective in young and middle-aged women.

No Effect of decision support on missed opportunities for human papillomavirus vaccination
Stephanie L. Mayne, Nathalie E. duRivage, Kristen A. Feemster, et al

Missed opportunities for human papilloma virus (HPV) vaccination are common, presenting a barrier to achieving widespread vaccine coverage and...

Yes Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes
Tom Glass Hopkins, Nick Wood

Human papillomavirus (HPV) is the causative agent in cervical cancer and has been implicated in a range of other malignancies.

Yes Cost-effectiveness of human papilloma virus vaccination in low and middle income countries: A systematic review
Michaela Fesenfeld, Raymond Hutubessy, Mark Jit

The World Health Organization recommends establishing that human papillomavirus vaccination is cost-effective before vaccine introduction.